

ASTRAZENECA PLC  
Form 6-K  
September 01, 2017

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For the month of September 2017

Commission File Number: 001-11960

AstraZeneca PLC

1 Francis Crick Avenue  
Cambridge Biomedical Campus  
Cambridge CB2 0AA  
United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐ No ☒

If "Yes" is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b):  
82- \_\_\_\_\_

01 September 2017 15:00 BST

Transparency Directive  
Voting Rights and Capital

The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. As at 31 August 2017 the issued share capital of AstraZeneca PLC with voting rights is 1,265,897,109 ordinary shares of US\$0.25. No shares are held in Treasury. Therefore, the total number of voting rights in AstraZeneca PLC is 1,265,897,109.

The above figure for the total number of voting rights may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, AstraZeneca PLC under the UK Financial Conduct Authority's Disclosure and Transparency Rules.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

For more information, please visit [www.astrazeneca.com](http://www.astrazeneca.com) and follow us on Twitter @AstraZeneca.

Media Relations

|                  |           |                  |
|------------------|-----------|------------------|
| Esra Erkal-Paler | UK/Global | +44 203 749 5638 |
| Rob Skelding     | UK/Global | +44 203 749 5821 |
| Karen Birmingham | UK/Global | +44 203 749 5634 |
| Matt Kent        | UK/Global | +44 203 749 5906 |
| Jacob Lund       | Sweden    | +46 8 553 260 20 |
| Michele Meixell  | US        | +1 302 885 2677  |

Investor Relations

|                     |                                                  |                  |
|---------------------|--------------------------------------------------|------------------|
| Thomas Kudsk Larsen |                                                  | +44 203 749 5712 |
| Craig Marks         | Finance, Fixed Income, M&A                       | +44 7881 615 764 |
| Henry Wheeler       | Oncology                                         | +44 203 749 5797 |
| Mitchell Chan       | Oncology                                         | +1 240 477 3771  |
| Christer Gruvris    | Diabetes; Autoimmunity, Neuroscience & Infection | +44 203 749 5711 |
| Nick Stone          | Respiratory; Brilinta                            | +44 203 749 5716 |
| US toll free        |                                                  | +1 866 381 7277  |

Adrian Kemp  
Company Secretary

AstraZeneca PLC

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 1 September 2017

By: /s/ Adrian Kemp

Name: Adrian Kemp

Title: Company Secretary